비/비인강 비호즈킨 림프종의 임상양상과 예후 인자

• 영문명: Clinical Features and Prognostic Factors in 41 Patients of Primary Nasal/Nasopharyngeal Non-Hodgkin's Lymphoma: Prognostic Significance of Immunophenotype
• 발행기관: 대한두경부종양학회
• 저자명: 박순서(Soon Seo Park) 서철원(Cheol won Suh) 박종범(Jong Beom Park) 박지운(Ji Woon Park) 임소덕(Soo Duk Lim) 허주령(Joo ryung Huh) 남순열(Soon Yuhl Nam) 김상윤(Sang Yoon Kim) 이호규 장혜숙(Hye sook Chang) 김태원(Tae Won Kim) 이제환(Je Hwan Lee) 김성배(Sung Bae Kim) 김상위(Sang We Kim) 이규형(Kyoo Hyung Lee) 이정신(Jung Shin Lee) 김우건(Woo Kun Kim) 김상희(Sang Hee Kim)
• 간행물 정보: 『대한두경부종양학회지』제15권 제2호, 149~155쪽, 전체 7쪽
• 주제분류: 의약학 > 종양학
• 파일형태: PDF
• 발행일자: 1999.11.30

영문 초록

Objectives: To study the clinical features of the primary nasal/nasopharyngeal non-Hodgkin's lymphomas and to evaluate the implication of immunophenotyping as a prognostic factor. Patients and Methods: From January 1990 to December 1997,41 patients(median age, 41 years) of primary nasal/nasopharyngeal non-Hodgkin's lymphoma were studied. The clinical records and paraffin-embedded tissue blocks were reviewed retrospectively. The histologic features, immunophenotypic findings(pan-T, pan-B, CD3, CD56) and Epstein-Barr virus in situ hybridizatios were examined. The prognostic factors for clinical outcome were evaluated in these patients. According to Ann-Arbor system, there were 30 patiets(73%) with stage IE, 4(10%) with stage IIE, 3(7%) with stage IIIE, 4(10%) with stage IVE lymphoma. Among the patients with stage IE/IIE, 4 patients received local radiation alone, 4 received chemotherapy alone, 25 received combination chemotherapy and radiotherapy and 1 refused treatment. The patients with stage IIIE/IVE were given combination chemotherapy and radiotherapy. Results: Immunophenotyping were performed in 40 patients and staining results were as follows: 3(7%) patients with B cell, 17(42%) with T cell, 18(44%) with NK/T cell(CD56 positive), and two patients with unclassifiable result. Epstein-Barr(EB) virus in situ hybridization were performed in 28 patients and 23(82%) patients had positive EBV-encoded RNAs(EBERs). 21(55%) patients achieved a complete remission. There was no difference in complete remission between radiation alone and combination therapy. With median follow-up of 30 months, 5-years disease free survival of complete responders was 60% and 5-years overall survival rate was 36%. Multivariate analysis showed that better overall survival was related with absence of B symptoms, ECOG performance ≤1 and non-NK cells. Conclusion: Most of all cases were positive for EBER. Since NK/T phenotype carried the worst prognosis, analysis for CD56 expression should be done. Further prospective studies were warranted to evaluate the role of chemotherapy in stage IE/IIE.

목차

Abstract

서론

대상 및 방법

결과

고찰

결론

References